Creative Medical Technology Holdings (CELZ) Total Liabilities (2010 - 2026)
Creative Medical Technology Holdings' (CELZ) quarterly Total Liabilities came in at $698595.0 in Q2 2026, up 151.62% year-over-year from $277644.0 in Q2 2025, and up 127.08% quarter-over-quarter from $307649.0 in Q1 2026.
Analysis
Creative Medical Technology Holdings (CELZ) Total Liabilities (2010 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Total Liabilities for 17 consecutive years, with $698595.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Total Liabilities rose 151.62% year-over-year to $698595.0 in Q2 2026; TTM through Jun 2026 was $698595.0, a 151.62% increase from a year earlier, with the FY2025 full-year figure at $284880.0, down 13.05% from the prior year.
- Total Liabilities was $698595.0 for Q2 2026 at Creative Medical Technology Holdings, up from $307649.0 in the prior quarter.
- Over five years, Total Liabilities peaked at $3.3 million in Q4 2022 and troughed at $261353.0 in Q3 2025.
- A 5-year average of $534950.3 and a median of $378033.5 in 2022 frame the typical range for Total Liabilities.
- Across the five-year window, Total Liabilities surged 216.21% in 2022 and sank 88.82% in 2023, its largest moves.
- Over 5 years, Total Liabilities stood at $3.3 million in 2022, then slumped by 88.82% to $371394.0 in 2023, then declined by 11.78% to $327644.0 in 2024, then fell by 13.05% to $284880.0 in 2025, then jumped by 145.22% to $698595.0 in 2026.
- The last three Total Liabilities figures came in at $698595.0 (Q2 2026), $307649.0 (Q1 2026), and $284880.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | 141.52 Mn |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | 904.22 Mn |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | 179.49 Mn |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | 521.30 Mn |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | 661.05 Mn |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | 318.91 Mn |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | 126.72 Mn |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | 1.66 Bn |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | 132.83 Mn |
| 10 | Creative Medical Technology Holdings | 1.48 Mn | 1.50 Mn | - | 698,595.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 698,595.00 |
| Mar 31, 2026 | 307,649.00 |
| Dec 31, 2025 | 284,880.00 |
| Sep 30, 2025 | 261,353.00 |
| Jun 30, 2025 | 277,644.00 |
| Mar 31, 2025 | 286,387.00 |
| Dec 31, 2024 | 327,644.00 |
| Sep 30, 2024 | 330,908.00 |
| Jun 30, 2024 | 376,272.00 |
| Mar 31, 2024 | 390,959.00 |
| Dec 31, 2023 | 371,394.00 |
| Sep 30, 2023 | 421,159.00 |
| Jun 30, 2023 | 398,527.00 |
| Mar 31, 2023 | 407,536.00 |
| Dec 31, 2022 | 3.32 Mn |
| Sep 30, 2022 | 396,957.00 |
| Jun 30, 2022 | 389,795.00 |
| Mar 31, 2022 | 379,795.00 |
| Dec 31, 2021 | 1.05 Mn |
| Sep 30, 2021 | 3.50 Mn |